This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension

This study has been completed.
Information provided by:
Hospital Clinic of Barcelona Identifier:
First received: January 3, 2008
Last updated: NA
Last verified: January 2008
History: No changes posted
The purpose of this study is to evaluate the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG), as a surrogate marker of prognosis, and its safety in patients with cirrhosis and portal hypertension.

Condition Intervention Phase
Cirrhosis Portal Hypertension Drug: Simvastatin Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IV-II Randomized, Multicenter, Placebo-Controlled Double-Blind Clinical Trial Evaluating the Effects of Continuous Simvastatin Administration on Hepatic and Systemic Hemodynamics in Patients With Cirrhosis.

Resource links provided by NLM:

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Changes in hepatic venous pressure gradient (HVPG) [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Changes in systemic hemodynamics [ Time Frame: 4 weeks ]
  • Changes in liver function tests [ Time Frame: 4 weeks ]

Enrollment: 59
Study Start Date: March 2004
Study Completion Date: November 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: A
Placebo treatment
Drug: Placebo
Placebo with the same characteristics of the drug and at the same dose
Experimental: B Drug: Simvastatin
20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met

Detailed Description:
Statins exert beneficial vascular effects independently of cholesterol reduction by improving endothelial dysfunction. In cirrhosis sinusoidal endothelial dysfunction further increases intrahepatic resistance and portal pressure. Previous studies have shown that statins improve hepatic endothelial dysfunction in cirrhosis, suggesting that statins could be an effective therapy for portal hypertension (PHT). This randomized controlled trial evaluated the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG), as a surrogate marker of prognosis, and its safety in patients with cirrhosis and PHT.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age between 18 and 75.
  2. Clinical, analytical, ultrasound or pathological criteria of cirrhosis.
  3. Severe sinusoidal portal hypertension (HVPG >12 mmHg)
  4. Signed informed consent

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Advanced liver disease defined as one of the following: Prothrombin rate <40%, Bilirubin >5 mg/dl, hepatic encephalopathy > grade I or Child-Pugh score >12).
  3. Portal vein thrombosis
  4. Multinodular hepatocellular carcinoma or single hepatocellular carcinoma > 5 cm.
  5. Heart, renal or respiratory failure
  6. Previous portal-systemic shunt
  7. Treatment with organic nitrates
  8. Hypersensitivity to HMG-CoA reductase inhibitors
  9. Previous treatment with HMG-CoA reductase inhibitors
  10. Treatment with calcium channel blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00594191

Hepatic Hemodynamic Laboratory. Liver Unit. Hospital Clinic.
Barcelona, Spain, 08036
Servicio de Gastroenterología, Hospital Ramón y Cajal
Madrid, Spain, 28871
Servicio de Gastroenterología, Hospital Universitario General Gregorio Marañón
Madrid, Spain
Sponsors and Collaborators
Hospital Clinic of Barcelona
Principal Investigator: Jaime Bosch, MD Hospital Clinic of Barcelona
  More Information

Responsible Party: Jaime Bosch /Professor of Medicine, University of Barcelona Identifier: NCT00594191     History of Changes
Other Study ID Numbers: SIMV-HTP2003
AEM 03-0434
Study First Received: January 3, 2008
Last Updated: January 3, 2008

Keywords provided by Hospital Clinic of Barcelona:
HMG-CoA reductase inhibitors
Portal hypertension
Variceal bleeding

Additional relevant MeSH terms:
Liver Cirrhosis
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Liver Diseases
Digestive System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017